Organogenesis Holdings Inc. (ORGO) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $2.51. It has a SharesGrow Score of 82/100, indicating a strong investment profile with 5 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of ORGO = $2.83 (+12.7% from the current price, the stock appears fairly valued). Analyst consensus target is ORGO = $9 (+258.6% upside).
Valuation: ORGO trades at a trailing Price-to-Earnings (P/E) of 7.8 (S&P 500 average ~25).
Financials: revenue is $564M, +8.1%/yr average growth. Net income is $37M, growing at +1350.1%/yr. Net profit margin is 6.6% (thin). Gross margin is 73.6% (-3.1 pp trend).
Balance sheet: total debt is $133M against $434M equity (Debt-to-Equity (D/E) ratio 0.31, conservative). Current ratio is 3.62 (strong liquidity). Debt-to-assets is 22.2%. Total assets: $599M.
Analyst outlook: 4 / 5 analysts rate ORGO as buy (80%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 83/100 (Pass), Past 100/100 (Pass), Health 100/100 (Pass), Moat 49/100 (Partial), Future 94/100 (Pass), Income 45/100 (Partial).
